First of all you donkey fuck I have not been on cafepharma until today. And second I actually did not ask you for your name. There are trolls on here. What moron would do that when I would never give my name up (Here's one clue I don't work at Takeda anymore) Second, if you looked at the new scripts vs pull through on refill you would know nationally there was a significant issue with getting refills. The vast majority of plans were not switching Rozerem to a schedule drug at the point of sale. There were managed care challenges, no doubt, but in the corporate meetings I was in while you were slinging donuts and coffee in your pathetic terroritory concern had nothing to do with inhouse concern was not switching at the pharmacy. It was about working to get coverage and working with marketing to get subclass unofficial hypnotic designation. This failed at the FDA level and the national level. When you are dealing with managed care plans you are not just dealing with bean counters. You are dealing with doctors and clinical pharmacists who know their science just like you do trolling around in your Jeep Liberty. I have had countless people describe what we called the "Science of Sleep" as an oversimplification of a complex process that was more complicated that MT1 MT2. We didn't invent those circadian rhythm receptors and other pharma companies dropped their research of them for an insomnia indication. Why would they do that? Because in order to get to 500,000 million plus in sales you would have to significantly expand the $2.5 + billion dollar sleep market. That's pretty hard to do you ass clown when you need virgins, seniors and no switches and have to take it more than a month. So the altruistic drug companies didn't come through on the other non-scheduled agents because they saw the math and knew the MOA may not be worth the cost of going to the sleep market. But only managed care is the big bad bully that doesn't care about the patients. It is NOT the job of managed care to make the call on what is safe and better for the patient when it comes to what is placed on formulary. Most of those decisions are made for them - the invisible hand. They do make those decisions but they are done with the partnership with medical associations or academies, the FDA and drug companies. Drug companies are not the only ones who want to influence formulary you jackass. It can be a slippery slope if they make those decisions on their own. You never ever give up on a drug that you think is highly efficacious. At the corporate level nobody wants to give up ground on their science. I'm not talking prouduct managers or senior managed individuals. I'm talking about Japan and those scientists behind development. So it should come to no surprise that we weren't freaking out about managed care status as much as does this drug have a viable and sustainable place in the insomnia market with our current promotional levels. Sleep phase shifting and jet lag were not an option as you well may have figured. So the decision to pull the promotional activities was not based on managed care. I am sure you have sold drugs that took plenty of time to get their shelf space in formualry. Maybe some of them were novel and required new disease state education. There were phenomenal people working behind the scenes to make Rozerem work. Equally great drug reps trying to hustle it one script at a time. I have been in this industry 23 years and I know for a fact (and expirence) that decisions to pull promotional activity are difficult and not just managed care. If that was the case Takeda would have packed their bags with Actos. Do you remember launching that? The first two years of formulary in some regions was horse shit. People were getting dropped to sulfs left and right. But why did we stick with it? Confidence in the drug and its place in the market.
So don't tell me to chill. Don't tell me I don't know what I am talking about. Here's another clue who I am. I am female. And I'm pretty sure I could wipe the floor with you when it comes to ambition, intelligence and drive.